MESSNER EXPECTED TO LAND AMGEN DRUG ACCOUNT

Anemia Treatment Aranesp Will Rival J&J's Procrit

Published on .

NEW YORK (AdAge.com) -- Amgen, Thousand Oaks, Calif., is expected to award an estimated $25 million account for new anemia treatment Aranesp to Havas Advertising's Messner Vetere Berger McNamee Schmetterer Euro RSCG, New York, people familiar with the matter said.

Aranesp will challenge Johnson & Johnson's Procrit.

Consultant Michael Markowitz & Associates, Santa Fe, N.M., handled the review.

Amgen did not return a call for comment.

Most Popular